Skip to main content

Advertisement

Table 3 Baseline characteristics of the study population

From: 68Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with18F-FDG, calcium burden and risk factors

Patient number Cancer type Systemic tumor therapy within the last 3 months Number of selected positive-uptake segments TBR mean
    FDG DOTATATE FDG DOTATATE
1 Renal cell cancer None 8 6 2.9 5.6
2 Follicular thyroid cancer TSH-suppressive therapy 7 2 2.6 3.3
3 Pheochromocytoma, metabolically active (normetanephrines, dopamines) None 3 4 2.1 3.9
4 Cancer of the gastric-esophageal junction Xeloda, single dose 2 days prior to FDG, 6 days prior to DOTATATE PET 0 0 1.5 1.8
5 NET (stomach) None 0 0 1.7 2.2
6 NET of unknown primary (liver metastases) None 6 3 2.2 3.4
7 Carcinoid (rectum) One cycle of Lu-177-DOTATATE 8 weeks prior to FDG, 9 weeks to DOTATATE PET 0 1 1.7 2.9
8 NET of unknown primary (liver metastases) None 5 2 2.1 2.9
9 NET (pancreas) One cycle of cisplatin/etoposide 1 week after FDG; 4 weeks prior to DOTATATE PET) 2 1 1.8 2.4
10 Carcinoid (lung), hormonally active None 1 2 1.7 2.6
11 NET of unknown primary (liver metastases) Sandostatin LAR, last injection 4 weeks prior to DOTATATE PET, then stopped 0 0 1.5 2
12 NET (ileum) None 2 1 1.7 2.8
13 NSCLC None 1 8 1.8 5.7
14 Papillary and follicular thyroid cancer TSH-suppressive therapy 2 4 1.9 3.5
15 Follicular thyroid cancer TSH-suppressive therapy 2 3 1.9 3.1
16 Uterine cancer None 0 0 1.4 1.3
  1. NET, neuroendocrine tumor; NSCLC, non-small cell lung cancer; TSH, thyroid-stimulating hormone.